Pharma Stocks
-
Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside
Ascendis Pharma earnings event and why it matters for shareholders Ascendis Pharma (NasdaqGS:ASND) recently reported second quarter 2026 results, with…
Read More » -
Share Market Today: Nifty 50, Bank Nifty
Indian Stock Market Today |Indian benchmark indices traded with a cautious bias on Monday, 24 August 2026, with Nifty holding above…
Read More » -
Oxford Nanopore Technologies (LSE:ONT) Leads A Busy UK Healthcare Stock Debate Beyond Big Pharma
Highlights Upbeat sequencing results contrasted with a finance-leadership change at a medical-products group, while large drugmakers remained defensive anchors. The…
Read More » -
Here’s why these four pharma stocks are in focus today
Shares of Caplin Point Laboratories, Aurobindo Pharma, Natco Pharma and Jubilant Pharmova are in focus on Monday, August 24, on…
Read More » -
Cardinal Health’s Pharma Chief Sold 7,354 Shares and Still Grew Her Stake by 47%. Here’s How That Happened
Deborah Weitzman, CEO of the PSS Segment, reported a sale of 7,354 shares of Cardinal Health, Inc. (CAH +0.46%) in…
Read More » -
Cardinal Health’s Pharma Chief Sold 7,354 Shares and Still Grew Her Stake by 47%. Here’s How That Happened
Deborah Weitzman, CEO of the PSS Segment, reported a sale of 7,354 shares of Cardinal Health, Inc. (NYSE:CAH) in a…
Read More » -
Global Big Pharma Merck’s stock price is soaring, revealing its strong presence in the U.S. stock ma..
사진 확대 Global Big Pharma Merck’s stock price is soaring, revealing its strong presence in the U.S. stock market. This…
Read More » -
Ecopipam Priority Review Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA)
In August 2026, Teva Pharmaceuticals announced that the FDA accepted and granted Priority Review to its New Drug Application for…
Read More » -
InnoCan Pharma’s Slide Deepens as Investors Weigh a Widening Gap Between Operations and Valuation
The disconnect at InnoCan Pharma has become hard to ignore. Earnings per share have compounded at roughly 45 percent annually…
Read More » -
ANI Pharmaceuticals (ANIP) Faces A Fresh Valuation Test Following Strong 2026 Results
ANI Pharmaceuticals earnings and guidance draw investor focus ANI Pharmaceuticals (ANIP) stock activity has been driven by fresh quarterly results…
Read More »